Commentary on transplant outcomes of 100 cases of living-donor ABO-incompatible kidney transplantation  

作　　者：Hideki Ishida 

机构地区：[1]Department of Organ Transplant Medicine,Tokyo Women's Medical University Hospital,Shinjuku-ku,Tokyo 162-8666,Japan.

出　　处：《Chinese Medical Journal》2022年第19期2301-2302,共2页中华医学杂志（英文版）

摘　　要：By the end of 1980,Japanese groups had started programs with ABO-incomparible kidney transplantation as a consequence of the very limited supply of cadaveric organs for transplantation.Since then,they have done successful transplantations across the blood type barrier in combina-tion with plasmapheresis and splenectomy.In Japan,the strategy for ABO-incompatible transplantation has changed with the development of the tacrolimus(FK)/mycophenolate mofetil(MMF)combination in 2000 and rituximab in 2005.1 In addition,preoperative 1-week administration of FK/MMF produced much more excellent results.Current graft survival(2005-2013)was almost over 90%in both ABO-incompatible at 9-year follow-up,which was comparable to ABO-compatible kidney trans-plantations.

关 键 词：ABO KIDNEY ORGANS 

分 类 号：R699.2[医药卫生—泌尿科学]